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Inherited human prion diseases, such as fatal familial insomnia (FFI) and familial
Creutzfeldt–Jakob disease (fCJD), are associated with autosomal dominant mutations in
the human prion protein gene PRNP and accumulation of PrPSc, an abnormal isomer of
the normal host protein PrPC, in the brain of affected individuals. PrPSc is the principal
component of the transmissible neurotoxic prion agent. It is important to identify molecu-
lar pathways and cellular processes that regulate prion formation and prion-induced
neurotoxicity. This will allow identiﬁcation of possible therapeutic interventions for indivi-
duals with, or at risk from, genetic human prion disease. Increasingly, Drosophila has
been used to model human neurodegenerative disease. An important unanswered ques-
tion is whether genetic prion disease with concomitant spontaneous prion formation can
be modelled in Drosophila. We have used pUAST/PhiC31-mediated site-directed muta-
genesis to generate Drosophila transgenic for murine or hamster PrP (prion protein) that
carry single-codon mutations associated with genetic human prion disease. Mouse or
hamster PrP harbouring an FFI (D178N) or fCJD (E200K) mutation showed mild
Proteinase K resistance when expressed in Drosophila. Adult Drosophila transgenic for
FFI or fCJD variants of mouse or hamster PrP displayed a spontaneous decline in loco-
motor ability that increased in severity as the ﬂies aged. Signiﬁcantly, this mutant PrP-
mediated neurotoxic ﬂy phenotype was transferable to recipient Drosophila that
expressed the wild-type form of the transgene. Collectively, our novel data are indicative
of the spontaneous formation of a PrP-dependent neurotoxic phenotype in FFI- or CJD-
PrP transgenic Drosophila and show that inherited human prion disease can be modelled
in this invertebrate host.
Introduction
Human prion diseases are a group of fatal transmissible neurodegenerative conditions that may be
genetic, acquired or arise sporadically. Collectively, these conditions include Creutzfeldt–Jakob disease
(CJD), fatal familial insomnia (FFI), Gerstmann–Sträussler–Scheinker disease (GSS), variant CJD and
kuru [1]. Prion diseases are characterised by the conversion of host PrP, the prion protein, from a
normal isomer PrPC into a misfolded and aggregated abnormal conformer PrPSc, which accumulates
in the brain of affected individuals [2]. Human prion diseases are transmissible, both within the
species and to experimental hosts [3]. According to the prion hypothesis, PrPSc is the major, if not
sole, component of the transmissible prion moiety [4]. Furthermore, expression of PrPC and its con-
version into PrPSc are considered necessary for prion-induced neurodegeneration [5–8].
Genetic human prion diseases, such as FFI, familial CJD (fCJD) and GSS, are associated with auto-
somal dominant mutations in the human prion protein gene PRNP [9–13]. More than 30 different
pathogenic mutations in PRNP have been identiﬁed which give rise to the following changes in PrPC:
single amino acid substitution; premature polypeptide stop codon or insertion of extra octapeptide
Accepted Manuscript online:
16 August 2017
Version of Record published:
20 September 2017
Received: 7 June 2017
Revised: 7 August 2017
Accepted: 15 August 2017
© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 3253
Biochemical Journal (2017) 474 3253–3267
DOI: 10.1042/BCJ20170462
repeats [14]. How these mutations in PRNP induce prion disease remains unclear although a generally held
view is that they increase the tendency of PrPC to form PrPSc by inﬂuencing prion protein structure [15–20].
In this context, mutations in PRNP may promote PrPC misfolding, enhance misfolded PrP to aggregate or
increase the stability of PrPSc. It is important to identify the molecular pathways and cellular processes that
regulate prion formation and prion-induced neurotoxicity. This will allow identiﬁcation of possible therapeutic
interventions for those individuals with genetic human prion disease, or those at risk in the case of asymptom-
atic carriers of these conditions.
Genetic forms of human prion diseases are difﬁcult to study in the natural host. These conditions are rela-
tively rare and are characterised by a long asymptomatic phase prior to the onset of clinical disease [3]. As a
consequence, attempts have been made to model genetic human prion diseases in mice transgenic for human,
bank vole or murine PrP carrying mutations associated with these conditions, or other modiﬁed forms of
mouse PrP [21–34]. The spontaneous development of a transmissible neurodegenerative phenotype has been
evidenced in some of these PrP transgenic mouse models while it was either unproven or contested in others.
Although instrumental in providing proof-of-principle that genetic human prion disease can be modelled in
experimental hosts that express mutated PrP, murine models of these conditions are relatively cumbersome and
experimental analysis relatively time consuming. Consequently, a more tractable genetically well-deﬁned animal
system is required to search for molecular and cellular pathways of prion-induced neurotoxicity associated with
genetic forms of human prion disease.
Increasingly, Drosophila melanogaster has been used to model human neurodegenerative disease [35–41].
This has arisen because the brains of Drosophila and mammalian species are composed of similar components
(i.e. neurons and neuronal circuitry), and the nature of ion channels, neurotransmitters and synaptic proteins
are highly conserved between mammals and the ﬂy [42–44]. In addition, Drosophila have several important
positive experimental advantages including a short lifespan, simple genetics and a well-characterised genome
that is amenable to transgenesis [45–47]. We have demonstrated that transmissible mammalian prion disease
can be modelled in the ﬂy [48–51]. Our studies have shown that PrP transgenic Drosophila develop a neuro-
toxic phenotype after exposure to exogenous prions that is associated with accumulation of PrPSc and is trans-
missible to PrP transgenic hosts, including mice, two crucial hallmarks of bona ﬁde mammalian prion diseases
[48–51]. These data show that Drosophila possess the cellular and molecular components required for mamma-
lian prion replication. An important unanswered question is whether genetic prion disease, concomitant with
the spontaneous formation of transmissible prions, can be modelled in Drosophila.
Here, we report the successful generation of PrP transgenic Drosophila that provide a novel host system to
model genetic human prion disease. We have used pUAST/PhiC31-mediated site-directed mutagenesis to gen-
erate Drosophila transgenic for murine or hamster PrP that carry single-codon mutations associated with FFI
(D178N) or fCJD (E200K) human prion disease. Mouse or hamster PrP harbouring these mutations showed
mild Proteinase K (PK) resistance when expressed in the ﬂy. Drosophila transgenic for FFI or fCJD variants of
mouse 3F4 or hamster PrP exhibited a progressive decline in locomotor ability during adulthood that increased
in severity as the ﬂies aged. This severity of effect was more pronounced in Drosophila that expressed PrP har-
bouring the fCJD rather than the FFI mutation, and was more severe in ﬂies that expressed hamster rather than
mouse prion protein that harboured these mutations. Signiﬁcantly, the mutant PrP-mediated neurotoxic ﬂy
phenotype was transferable to recipient Drosophila that expressed the wild-type form of the transgene.
Collectively, these novel data are indicative of the spontaneous formation of a PrP-dependent neurotoxic
phenotype in FFI- or fCJD-PrP transgenic Drosophila and show that genetic human prion disease can be mod-
elled in this invertebrate host.
Materials and methods
PrP amino acid numbering
Species-speciﬁc amino acid numbering for mouse, hamster and human PrP is used throughout this study [52].
Mouse and hamster PrP transgenes
We generated a panel of transgenes that comprised DNA encoding mature mouse or hamster PrP ﬂanked by
the coding sequence of an autologous N-terminal leader peptide and a C-terminal GPI (glycosylphosphatidyli-
nositol) signal sequence. The mouse and hamster PrP transgenes carried single-codon mutations that corre-
sponded to the human PrP mutations D178N or E200K, which are associated with inherited FFI and CJD,
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respectively [9–12]. The mouse PrP also carried two further amino acid substitutions L108M and V111M that
created the 3F4 epitope that is already present in wild-type human and hamster PrP [53]. The murine PrP
used here is hereafter referred to as mouse 3F4 (or mo3F4) PrP. In addition, we generated transgenes that
encoded either murine 3F4 PrP or hamster PrP without mutations associated with inherited human prion
disease, hereafter referred to as wild-type mouse 3F4 (or mo3F4WT) PrP or wild-type hamster (or haWT) PrP,
respectively. DNA encoding these various transgenes was ampliﬁed by PCR using as substrate pBSKSII plas-
mids that contained inserts that coded for each of these different mouse or hamster prion proteins and oligo-
nucleotide primers complementary to the 50- and 30-ends of these sequences. For the ampliﬁcation of mouse
PrP DNA, the primers were:
Forward: 50-GGC GAA TTC ATG GCG AAC CTT GGC TAC TGG-30
Reverse: 50-GTC CGC TCG AGT CAT CCC ACG ATC AGG AAG ATG-30
For the ampliﬁcation of hamster PrP DNA, the primers were:
Forward: 50-GGC GAA TTC ATG GCG AAC CTT AGC TAC TGG-30
Reverse: 50-GTC CGC TCG AGT CAT CCC ACC ATC AGG AAG ATG-30
The PCR was carried out in the presence of Pfu DNA polymerase (Promega) under reaction conditions that
comprised an initial denaturation at 95°C for 10 min followed by 35 cycles of denaturation at 94°C for 30 s,
primer annealing at 58°C for 30 s, primer extension at 72°C for 1 min and a ﬁnal extension of the 785 bp PCR
product at 72°C for 7 min (see Supplementary Data S2). The forward and reverse primers contained EcoR1 and
Xho1 restriction sites, respectively, that allowed directional cloning of the PCR product into the Drosophila
transgenesis vector pUASTattB. The reverse primer contained a stop codon ahead of the Xho1 restriction site.
The various pUASTattB DNA constructs were subsequently rescued by transformation in DH5α bacteria.
Plasmid DNA was isolated from transformed bacteria by an alkaline lysis method using the Qiagen maxiprep
kit and the PrP construct insert veriﬁed by DNA sequence analysis.
Drosophila S2 cell culture and transfection
Drosophila Schneider 2 (S2) cells were maintained in Schneider’s Drosophila medium (Invitrogen, Karlsruhe,
Germany) containing L-Glutamine and supplemented with 10% foetal calf serum. Cells were cultured at 25°C
in atmospheric air. S2 cells were plated 1 day prior to transfection. Transient co-transfections of
pUASTattB-PrP plasmids and the driver plasmid that expresses GAL4 under the control of the actin5C pro-
moter pWA-GAL4 [54] were carried out using Effectene (Qiagen, Hilden, Germany) according to the manufac-
turers’ instructions. S2 cells were analysed at various time points after transfection.
Immunoﬂuorescent staining and confocal laser scanning microscopy
Drosophila S2 cells were plated on ibidi dishes (Planegg/Martinsried, Germany) or coverslips were ﬁxed with
3% paraformaldehyde solution (pH 7.3) at 21°C for 10 min. In some cases, ﬁxed cells were subsequently per-
meabilised by treatment with 0.1% Triton X-100 at 21°C for 10 min. In cases where antigen retrieval was
required, proteins were denatured by the treatment of ﬁxed and permeabilised cells with 6 M guanidinium
hydrochloride (GdnHCl) at 21°C for 7 min. Cells were subsequently rinsed with either PBS in the case of
non-detergent-treated cells or in the case of detergent-treated samples, with 0.01% Triton X-100 in PBS
(PBST). Washed cells were incubated with mouse monoclonal anti-PrP antibody 4H11 [55] and the
Golgi-speciﬁc rabbit polyclonal antibody GM130 (Abcam, Cambridge, U.K.) at 37°C for 60 min. After three
washing steps in PBS or PBST, as appropriate, cells were incubated with Alexa Fluor-488-conjugated goat anti-
mouse IgG (Invitrogen, Karlsruhe, Germany) or Cy3-conjugated goat anti-rabbit IgG (Dianova, Hamburg,
Germany) at 21°C for 60 min. Nuclei were stained with Hoechst DNA staining dye (Sigma, Taufkirchen,
Germany). Confocal laser scanning microscopy was performed on an LSM 700 laser scanning microscope
(Zeiss, Göttingen, Germany).
Generation of PrP transgenic Drosophila
Site-speciﬁc transformation of pUASTattB-PrP constructs into the 51D ﬂy line (y[1] M{vas-int.Dm}ZH-2A w
[*]; M{3xP3-RFP.attP}ZH-51D) was performed by Bestgene, Inc. (CA, U.S.A.). Viable lines were maintained as
balanced stocks by conventional ﬂy crosses. PCR was performed on genomic DNA from each balanced ﬂy line
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to conﬁrm the presence of the correct PrP transgene at the 51D site (see Supplementary Information).
Cre-mediated removal of RFP from the ﬂy genome of each PrP variant and from non-transgenic 51D ﬂies was
performed by conventional ﬂy crosses using y[1] w[67c23] P{y[+mDint2] = Crey}1b; sna[Sco]/CyO
(Bloomington Stock 766) [48] obtained from the Department of Genetics, Cambridge University, U.K. The
elav-GAL4 ﬂy line (P{w[+mW.hs] = GawB}elav[C155]) was also obtained from the Department of Genetics,
Cambridge University, U.K. All ﬂy lines were raised on standard cornmeal media [56] at 20 or 25°C, main-
tained at low-to-medium density. Flies were used in the assays described below or harvested at various time
points and then frozen at −80°C until required.
Preparation of Drosophila head homogenate
Whole ﬂies in an eppendorf tube were frozen in liquid nitrogen for 10 min and then vortexed for 2 min to
cause decapitation. Individual ﬂy heads (1 : 1 mixture of male and female) were isolated and placed in clean
eppendorf tubes using a ﬁne paint brush. PBS (pH 7.4) was added to give 1 ml/head and homogenates were
prepared by manual grinding of ﬂy heads in the eppendorf tubes with sterilised plastic pestles. Homogenates
for western blot of PrP were prepared by processing 20 ﬂy heads in 20 ml of lysis buffer [50 mM Tris (pH 7.5),
100 mM NaCl, 0.5% (v/v) Nonidet P-40 and 1 mM 4-(2-aminoethyl) benzenesulfonyl ﬂuoride (AEBSF)] fol-
lowed by 10 min sonication on ice. Homogenates for protein misfolding cyclic ampliﬁcation (20 heads prepared
in 20 ml of PBS [pH 7.4]) or for ﬂy-to-ﬂy transmission (secondary passage samples; 300 heads prepared in
300 ml of PBS [pH 7.4]) were prepared from Drosophila harvested at 30 days of age. In some cases, ﬂy head
homogenate was treated with 0–5 mg/ml PK at 37°C for 30 min in lysis buffer without AEBSF prior to western
blot analysis. For PCR analysis, ﬁve ﬂy heads were homogenised in 25 ml of PK–lysis buffer [10 mM Tris (pH
8), 1 mM EDTA, 25 mM NaCl and 200 mg/ml PK], incubated at 37°C for 30 min and followed by incubation
at 80°C for 10 min.
SDS–PAGE and western blot
Fly head homogenate was mixed with an equal volume of 2×-strength Laemmli loading buffer, boiled for
10 min, cooled on ice and then centrifuged at 13 000×g for 10 min at 18°C to remove debris. Fly head hom-
ogenate was subjected to SDS–PAGE run under reducing conditions and western blot as described in detail
previously [57], except that the nitrocellulose membranes were probed with a 1 : 2000 dilution of anti-PrP
monoclonal antibody Sha31 [58]. For analysis of Drosophila S2 cells by western blot, the cells were pelleted,
resuspended in SDS sample buffer and sonicated. After boiling, samples were analysed on NuPAGE Novex
4–12% Bis–Tris gels (Invitrogen, Darmstadt, Germany). Proteins were transferred onto a polyvinylidene
diﬂuoride membrane (GE Healthcare, Buckinghamshire, U.K.), and PrP was detected by probing with anti-PrP
monoclonal antibody 4H11 [55].
Prion inoculation of Drosophila
Drosophila at the larval stage of development were exposed to ﬂy head or mouse brain homogenate. In the case
of ﬂy-to-ﬂy prion transmission, ﬂy head homogenate contained the equivalent of 20 ﬂy heads (prepared from
30-day-old ﬂies) per 250 ml PBS. In the case of mouse-to-ﬂy prion transmission, homogenate comprised a
10−2 dilution (v/v) in PBS of adult mouse brain. Two hundred and ﬁfty microlitres of either ﬂy head or mouse
brain homogenate were added to the top of the cornmeal that contained third instar Drosophila larvae in 300
plastic vials. Flies were transferred to fresh, non-treated vials following eclosion.
Negative-geotaxis climbing assay
The locomotor ability of ﬂies was assessed in a negative-geotaxis climbing assay [59] that was initiated with 45
(3 × n = 15) age-matched, pre-mated female ﬂies in each treatment group. Drosophila were placed in adapted
plastic 25 ml pipettes that were used as vertical climbing columns and allowed to acclimatise for 30 min prior
to assessment of their locomotor ability. Flies were tapped to the bottom of the pipette (using the same
number and intensity of taps on each occasion) and then allowed to climb for 45 s. At the end of the climbing
period, the number of ﬂies above the 25 ml mark (top), the number below the 2 ml mark (bottom) and the
number in between the 2 and 25 ml mark were recorded. This procedure was performed three times at each
time point. The performance index (PI) was calculated for each group of 15 ﬂies (average of three trials) using
the formula PI = 0.5 × (ntotal + ntop− nbottom)/ntotal where ntotal is the total number of ﬂies, ntop is the
total number of ﬂies at the top and nbottom is the total number of ﬂies at the bottom. A PI value of 1 is
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recorded if all ﬂies climb to the top of the tube, whereas the value is 0 if no ﬂies climb the tube past the 2 ml
mark. The mean PI ± SD at individual time points for each treatment group was plotted as a regression line.
Statistical analysis
Statistical analysis of the data was performed by one-way analysis of variance (ANOVA), together with Tukey
honestly signiﬁcant difference (HSD) for post hoc analysis or the paired-samples Student’s t-test using Prism
(GraphPad Software, Inc., San Diego, U.S.A.).
Results
Mouse 3F4 and hamster PrP variants
To model spontaneous prion formation in Drosophila, we ﬁrst generated a panel of DNA constructs that
encoded variants of mouse 3F4 or hamster PrP in the ﬂy transgenesis vector pUASTattB. These PrP variants
contained single amino acid substitutions associated with the human prion diseases FFI and fCJD [9–12].
Figure 1 shows the C-terminal domain location of the human prion protein mutations analysed here. All of the
murine 3F4 prion protein variants were generated in mouse PrP that carried two additional amino acid
sequence substitutions, namely L108M and V111M. The addition of these two methionine residues in murine
PrP created the 3F4 epitope [53], naturally present in human and hamster prion protein, and this protein is
hereafter referred to as mouse 3F4 PrP (or mo3F4), where appropriate. The constructs that encoded variants of
mouse 3F4 and hamster PrP were generated with DNA encoding their autologous N-terminal leader peptide
and C-terminal GPI-signal sequence in order to permit cell-surface protein expression. Mouse PrP (and the
3F4 variant used here) has one less amino acid compared with human and hamster PrP in the N-terminal
region of the polypeptide; therefore, species-speciﬁc amino acid numbering is used throughout this text [52].
Mouse 3F4 and hamster PrP transgenes are expressed in Drosophila cells
We ﬁrst veriﬁed that the variants of mouse 3F4 and hamster PrP investigated here could be expressed from the
pUASTattB transgenesis vector. To do so, we transiently transfected Drosophila S2 cells with each of the PrP
constructs together with the plasmid pWA-GAL4 [54], which was used to drive prion protein expression. We
subsequently determined the topological location and relative expression level of each of the different PrP var-
iants by confocal microscopy and western blot analysis, respectively.
The data in Figure 2 show that variants of mouse 3F4 and hamster (ha) PrP, expressed with their autologous
N-terminal leader peptides, were located on the surface of transfected S2 cells, in a manner similar to that of
the control PrP expressed with a ﬂy leader peptide [(VRQ(GPI)] [48]. The mo3F4CJD (E199K) and haCJD
(E200K) variants were present on the cell surface at a similar level to their respective control proteins
mo3F4WT (wild-type mouse 3F4) and haWT (wild-type hamster) PrP. In contrast, the mo3F4FFI (D177N) and
haFFI (D178N) were weakly represented at the cell surface of transfected S2 cells. We subsequently investigated
Figure 1. PRNP mutations associated with genetic forms of human prion disease.
(a) Line diagram representation of the human PRNP gene and PrP protein, with the amino acid codons in the C-terminal
domain of the human prion protein analysed in the present study highlighted. (b) Ribbon structure model of the C-terminal
domain of human PrP with amino acids D178 (blue) and E200 (red) highlighted. Polypeptide backbone and α-helices shown in
green; β-strands are shown in gold, and the disulphide bond between amino acids S179 and S222 shown in yellow.
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whether the reduced cell-surface expression of some of the variants of murine 3F4 and hamster PrP was a con-
sequence of their failure to reach the secretory pathway. To do so, transiently transfected S2 cells were permea-
bilised and co-stained for the detection of PrP expression and the Golgi marker GM130. The data in Figure 2
show that the mo3F4FFI and haFFI variants showed partial co-localisation with the Golgi.
The reduced expression of some of the mouse 3F4 and hamster PrP variants may have arisen because the
mutations they carried adversely affected stability of the prion protein [15–19]. Alternatively, the conformation
of the PrP variant may have restricted its detection by confocal immunoﬂuorescence. To investigate this, lysates
of transfected S2 cells were prepared, denatured and subjected to SDS–PAGE and western blot for the detection
of total PrP expression. The data in Figure 3 show that the mo3F4CJD and haCJD variants were present at
similar levels in S2 cells compared with their respective control PrP proteins, whereas the mo3F4FFI and haFFI
mutants were expressed at a lower level. The data also show that the mo3F4FFI and haFFI variants displayed a
different molecular proﬁle in terms of glycosylation to that of the mo3F4CJD and haCJD variants and their
respective control PrP proteins.
Collectively, the data in Figures 2 and 3 showed that murine 3F4 and hamster PrP variants were successfully
expressed from the Drosophila transgenesis vector pUASTattB and support the view that mutations in human
PrP appear to affect its stability or its ability to traverse the secretory pathway [60].
We subsequently selected the mo3F4FFI and haFFI, mo3F4CJD and haCJD PrP variants, and their respective
control proteins mo3F4WT and haWT PrP for expression in Drosophila. These particular PrP variants were
chosen for three reasons. First, they were efﬁciently expressed in Drosophila cells in vitro. Second, they allowed
a direct comparison of the pathogenic potential of the same FFI- and fCJD-associated mutations in a mouse
3F4 PrP and hamster PrP context. Third, their use allowed a comparison between the effect of mouse 3F4 PrP
variants expressed in Drosophila and the same PrP variants expressed in mice where they have been shown to
be associated with the spontaneous formation of transmissible prions [27,28].
Generation of Drosophila transgenic for mouse 3F4 or hamster PrP variants
We generated Drosophila transgenic for variants of mouse 3F4 or hamster PrP by pUASTattB/
PhiC31-mediated site-directed mutagenesis [61] whereby the different PrP transgenes were targeted to the
same genomic landing site in each respective ﬂy line (see Supplementary Data S1). This transgenesis strategy
avoids potential insertional effects, including mutations or alterations in gene expression locally, but also those
that affect the expression of the transgenes themselves [62]. We subsequently removed the RFP cassette located
at the 51D site by Cre-mediated cleavage in each PrP transgenic ﬂy line. This was performed in order to
exclude the potential contribution of pigment-associated effects on neuronal integrity and survival [63].
Drosophila transgenic for variants of mouse 3F4 or hamster PrP were subsequently crossed with the
elav-GAL4-driver line to allow pan neuronal expression of these variant prion proteins in the ﬂy.
We investigated the molecular proﬁle and expression level of the murine 3F4 and hamster PrP variants in
Drosophila by immunobiochemical detection methods. The western blot analysis in Figure 4 shows that there
was efﬁcient expression of the FFI and fCJD variants of mouse 3F4 and hamster PrP in Drosophila, which com-
prised multiple bands of molecular mass of ∼29–31 kDa, similar to that of mouse and hamster PrP expressed
in the ﬂy reported elsewhere [64,65]. The mo3F4FFI and mo3F4CJD PrP variants were expressed in Drosophila
at a level, and with a molecular proﬁle in terms of glycosylation similar to that of mo3F4WT PrP. Similar trends
were seen for the hamster PrP variants haFFI and haCJD in comparison with haWT PrP expressed in Drosophila.
Mutations in human PrP that segregate with FFI and fCJD in the natural host are associated with the forma-
tion of disease-associated PrP, which shows differences in its state of aggregation and resistance to proteolytic
digest compared with the normal form of the prion protein [3]. Consequently, we investigated whether mouse
3F4 or hamster PrP variants expressed in Drosophila displayed properties reminiscent of disease-associated
prion protein, namely resistance to proteolytic digest.
The sensitivity to proteolytic digest of mouse 3F4 or hamster PrP variants expressed in Drosophila was exam-
ined by PK treatment of ﬂy head homogenate followed by analysis of the reaction products by SDS–PAGE and
western blot probed with an anti-PrP monoclonal antibody. The data in Figure 5 show that mouse 3F4 PrP
and hamster PrP carrying either an FFI or fCJD-associated mutation displayed an increased resistance to rela-
tively low concentrations of PK that completely digested the respective control PrP protein. The level of
PK-resistant prion protein in FFI and fCJD-PrP transgenic Drosophila was similar in young adult Drosophila (5
days of age, data shown) to that seen in older ﬂies (30 days of age, data not shown). Collectively, these observa-
tions showed that variants of mouse 3F4 and hamster PrP were successfully expressed in Drosophila, and that
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PrP mutations associated with genetic prion disease affect the molecular properties of the PrP when it is
expressed in the ﬂy.
Reduced locomotor ability of Drosophila transgenic for mouse 3F4 or hamster
PrP variants
We next investigated the locomotor ability of Drosophila transgenic for variants of murine 3F4 or hamster PrP
in order to determine whether FFI and fCJD-associated prion protein mutations induced a spontaneous neuro-
toxic phenotype in the ﬂy. To do so, we performed a negative-geotaxis climbing assay [50] using adult PrP
transgenic Drosophila. We compared the response of ﬂies maintained and assessed at 20 and 25°C in an
attempt to regulate the expression level of PrP in Drosophila through the temperature dependence of GAL4
activity in the ﬂy [66].
The data in Figure 6 show the locomotor ability, expressed as a PI, of Drosophila transgenic for variants of
murine 3F4 or hamster PrP as the ﬂies aged after hatching. While expression of mo3F4WT and haWT PrP in
Drosophila had a negative effect upon the locomotor activity of the ﬂy as reported by others [65,67,68], espe-
cially at 25°C, this effect was exacerbated by FFI and fCJD-associated prion protein mutations. Adult
Figure 2. Confocal microscopy of Drosophila S2 cells transiently transfected with mouse 3F4 or hamster PrP constructs.
Drosophila S2 cells were transiently co-transfected with pUASTattB plasmids which contained insert DNA that encoded (a) mouse 3F4 PrP variants;
(b) hamster PrP variants or (c) ovine VRQ(GPI), together with the pWA-GAL4-driver plasmid. Cells 24 h post-transfection were ﬁxed with or without
prior permeabilisation by treatment with Triton X-100. Mock-transfected cells were treated with the Effectene transfection reagent. Prepared cells
were subsequently reacted with the anti-PrP monoclonal antibody 4H11, and additionally with the anti-Golgi polyclonal antibody GM130 in the case
of permeabilised cells, prior to confocal microscopy. Nuclei were counterstained with Hoechst. Scale bar: 2 μm.
Figure 3. Western blot detection of mouse 3F4 and hamster PrP expression in transiently transfected Drosophila S2
cells.
Drosophila S2 cells were transiently co-transfected with pUASTattB that contained insert DNA that encoded mouse 3F4 or
hamster PrP constructs, together with the pWA-GAL4-driver plasmid. Control cells were treated with the Effectene transfection
reagent. Cell lysates were prepared 24 h post-transfection and subjected to SDS–PAGE, and western blot analysis with the
anti-PrP monoclonal antibody 4H11. (The haFFI D178N sample track is from a separate gel.) Molecular mass marker values are
shown on the left in kDa.
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Drosophila transgenic for mo3F4CJD PrP showed a signiﬁcantly enhanced decline in locomotor ability com-
pared with control ﬂies that expressed mo3F4WT PrP when maintained at 20°C (Figure 6a) and 25°C
(Figure 6b; P < 0.001 in both cases). Adult ﬂies transgenic for mo3F4FFI PrP showed a signiﬁcantly enhanced
decline in locomotor ability compared with control ﬂies when maintained at 25°C (Figure 6b; P = 0.022). The
mo3F4CJD variant was associated with a more severe neurotoxic ﬂy phenotype compared with the response
induced by mo3F4FFI PrP (Figure 6a,b). Adult Drosophila transgenic for haCJD PrP showed a signiﬁcantly
enhanced decline in locomotor ability compared with control ﬂies that expressed haWT PrP when maintained
at 20°C (Figure 6c) and 25°C (Figure 6d; P < 0.001 and P = 0.0153, respectively). Adult Drosophila transgenic
for haFFI PrP did not show an enhanced decline in locomotor ability compared with control haWT PrP trans-
genic ﬂies when maintained at 20 or 25°C (Figure 6c,d; P > 0.05 in both cases). Collectively, these data suggest
that expression in Drosophila of rodent PrP harbouring mutations associated with genetic forms of human
prion disease induces a spontaneous neurotoxic phenotype in the ﬂy. We found no discernible difference in
PrP expression level between ﬂies maintained at either 20 or 25°C (data not shown). This suggested that PrP
transgenic Drosophila maintained at the lower temperature showed less non-speciﬁc toxicity, possibly because
of reduced metabolic activity compared with ﬂies maintained at the higher temperature.
Transmission of spontaneously induced neurotoxicity in PrP transgenic
Drosophila
A hallmark feature of prion diseases is their transmissibility, a characteristic feature mediated by prions includ-
ing those that develop spontaneously in individuals with genetic forms of these conditions [1,3]. Accordingly,
we performed a series of transmission experiments in the ﬂy in order to establish whether the spontaneous
neurotoxic phenotype observed in Drosophila transgenic for variants of murine 3F4 or hamster PrP was trans-
ferable between hosts and therefore potentially prion-mediated.
We ﬁrst determined whether PrP transgenic Drosophila were susceptible to an exogenous source of spontan-
eously formed prions. To do so, we performed a mouse-to-ﬂy transmission experiment whereby mo3F4WT PrP
transgenic Drosophila were exposed, at the larval stage, to brain homogenate from knockin mice that express
Figure 4. Western blot detection of mouse 3F4 and hamster prion protein expression in PrP transgenic Drosophila.
Fly head homogenates were prepared from 5-day-old Drosophila transgenic for pan neuronal expression of mouse 3F4 PrP
(left hand panel) or hamster PrP (right hand panel). Homogenates were analysed by SDS–PAGE and western blot with anti-PrP
monoclonal antibody Sha31. The equivalent of six ﬂy heads was run per track. Molecular mass marker values are shown on
the left hand side in kDa.
Figure 5. Mildly PK-resistant prion protein in Drosophila transgenic for variants of mouse 3F4 or hamster PrP.
Head homogenates were prepared from 5-day-old Drosophila transgenic for mouse 3F4 or hamster PrP crossed with the
elav-GAL4 pan neuronal driver ﬂy line and maintained at 25°C. Homogenates were treated with or without PK (0–5 mg/ml) and
subsequently analysed by SDS–PAGE and western blot with the anti-PrP monoclonal antibody Sha31. The equivalent of one
ﬂy head was run per track. Molecular mass marker values are shown on the left hand side in kDa.
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mo3F4FFI or mo3F4CJD PrP variants. Brain homogenates from these mice are an established source of spontan-
eously generated transmissible prions [27,28]. After hatching, prion-exposed ﬂies were assessed for their loco-
motor ability by a negative-geotaxis climbing assay. The data in Figure 7 show that adult Drosophila transgenic
for mo3F4WT PrP showed a signiﬁcantly enhanced decline in locomotor ability after exposure at the larval
stage to brain homogenate from mo3F4FFI (P = 0.0469 over days 11–25 in Expt. 1 and P = 0.0056 over days 1–
25 in Expt. 2) or mo3F4CJD (P = 0.0203 over days 1–25 in Expt. 1 and P = 0.0097 over days 1–25 in Expt. 2)
PrP knockin mice, compared with the response seen after exposure to control brain homogenate from
mo3F4WT PrP knockin mice. The response induced by mo3F4CJD PrP mouse brain material was greater than
that induced by similar material from mo3F4FFI PrP mice, which correlated with the increase in severity of
prion disease seen in the original donor mice [27,28]. These data show that PrP transgenic Drosophila were
susceptible to the neurotoxicity induced by exogenously supplied spontaneously generated prions.
We next performed a ﬂy-to-ﬂy transmission study in order to determine whether the spontaneous neuro-
toxic phenotype seen in Drosophila transgenic for murine 3F4 or hamster PrP variants was transferable. In
these experiments, Drosophila transgenic for either mo3F4WT or haWT PrP were exposed, at the larval stage, to
head homogenate prepared from FFI and fCJD mouse 3F4 or hamster PrP transgenic ﬂies, respectively. After
hatching, inoculated ﬂies were assessed for their locomotor ability by a negative-geotaxis climbing assay. The
data in Figure 8 show that head homogenate from Drosophila transgenic for mouse 3F4 PrP variants
(Figure 8a,b) and hamster PrP variants (Figure 8c,d) induced a mild but signiﬁcant accelerated decline in loco-
motor activity compared with that from age-matched wild-type mouse 3F4 or wild-type hamster PrP ﬂies (P≤
0.05 in all cases). Head homogenate from ﬂies transgenic for mo3F4CJD or haCJD PrP generally induced a more
Figure 6. Reduced locomotor ability in Drosophila transgenic for variants of mouse 3F4 or hamster PrP.
Adult Drosophila transgenic for pan neuronal expression of mouse 3F4 PrP (a) and (b) or hamster PrP (c) and (d) were
maintained at either 20°C (a) and (c) or 25°C (b) and (d), and assessed for their locomotor ability by a negative-geotaxis
climbing assay. The data shown are linear regression plots of the mean PI ± SD for three groups of ﬂies per time point
calculated as described in the Materials and Methods. Green line, mo3F4WT (a) and (b) or haWT (c) and (d) PrP ﬂies; red line,
mo3F4CJD or haCJD PrP ﬂies (where appropriate); blue line, mo3F4FFI or haFFI PrP ﬂies (where appropriate); black line,
non-transgenic 51D ﬂies. Statistical analysis was performed by using the paired-samples t-test.
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marked decline in locomotor ability in recipient ﬂies compared with that from ﬂies that expressed mo3F4FFI or
haFFI PrP. This correlated with the more pronounced decline in spontaneous locomotor ability exhibited by
mo3F4CJD and haCJD PrP transgenic Drosophila compared with mo3F4FFI and haFFI PrP transgenic ﬂies (see
Figure 6). Furthermore, head homogenate from 30-day-old Drosophila transgenic for mouse 3F4 PrP or
hamster PrP variants generally induced a more pronounced accelerated decline in locomotor ability in recipient
ﬂies compared with the response induced by material from equivalent 5-day-old ﬂies (data not shown).
Collectively, these transmission studies suggest that Drosophila transgenic for mouse or hamster PrP that
harbour either an FFI or fCJD-associated mutation spontaneously generate a transferable toxic moiety, one that
accumulates with time as the ﬂies age.
Discussion
We have generated Drosophila transgenic for mouse or hamster PrP that carried single-codon human muta-
tions associated with FFI or fCJD, namely D178N and E200K, respectively. This was performed in order to
begin to generate a tractable animal model to probe the mechanism of spontaneous prion-induced neurotox-
icity. We used pUASTattB/PhiC31-mediated site-speciﬁc transgenesis to integrate subtly different PrP trans-
genes into the same unique landing site in the Drosophila genome. This created the ﬁrst allelic series of ﬂy
lines that express PrP from different species harbouring mutations associated with different human prion dis-
eases. Targeted transgenesis enabled a direct comparison of the effects of different PrP variants expressed in
Drosophila. This approach avoids complications that may arise through random insertional transgenesis, such
as silencing, activation or mutation of native genes, or variable transgene expression caused by genomic pos-
ition effects [62].
The PrP transgenes used here encoded the mature form of mouse 3F4 or hamster prion protein ﬂanked by
their autologous N-terminal leader peptide and C-terminal GPI-signal sequences. The rodent PrP transgenes
were efﬁciently expressed in Drosophila although the mo3F4FFI and haFFI, but not the mo3F4CJD and haCJD,
variants showed a somewhat reduced molecular mass proﬁle to that of mo3F4WT or haWT PrP, respectively. A
difference in the molecular proﬁle of mo3F4FFI PrP and mo3F4WT PrP was also evident when these proteins
were expressed in knockin mice [27]. Confocal microscopy of Drosophila S2 cells transiently transfected with
the various mouse 3F4 or hamster PrP transgenes showed that these prion protein variants were capable of cell-
surface expression. However, while mo3F4FFI and haFFI PrP entered the Golgi apparatus, both were present on
the plasma membrane of S2 cells at a lower level compared with their respective control proteins and the
mo3F4CJD and haCJD variants. It has been shown that mo3F4FFI PrP was localised principally in the Golgi and
Figure 7. Mouse-to-ﬂy transmission of spontaneous prion-induced neurotoxicity.
Drosophila transgenic for pan neuronal expression of mo3F4WT PrP were exposed at the larval stage to mouse brain
homogenate from mo3F4CJD PrP (red line); mo3F4FFI PrP (blue line); mo3F4WT (green line) PrP transgenic mice or PrP−/−
(black line) mouse brain homogenate. After hatching, adult Drosophila were assessed for their locomotor ability by a
negative-geotaxis climbing assay. The data shown are linear regression plots of the mean PI ± SD for three groups of ﬂies per
time point calculated as described in the Materials and Methods. Repeat experiments (a) 1 and (b) 2 are shown, each using
different mo3F4 PrP mice brain samples (n = 2, all aged ≥350 days). Statistical analysis was performed by using the
paired-samples t-test.
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present sparsely at the plasma membrane of mouse granule neurons, whereas the majority of wild-type mouse
PrP was present on the plasma membrane and in endosomes, and only a small fraction of the protein was
located in the endoplasmic reticulum and Golgi [22]. Furthermore, we have found here that mouse 3F4 PrP
and hamster PrP with either an fCJD- or FFI-associated mutation showed a mild resistance to PK compared
with the respective wild-type PrP protein. A similar resistance to PK digestion has been shown for mo3F4P101L
PrP expressed in Drosophila [67]. These observations are consistent with the view that mutations associated
with genetic forms of human prion disease that affect the stability and biochemistry of PrP [15–19,22,24] or its
ability to transit the secretory pathway [22,24,60,69] are manifest in the prion protein when expressed in
Drosophila.
Adult Drosophila transgenic for pan neuronal expression of mouse 3F4 or hamster PrP variants displayed a
neurotoxic phenotype, evidenced by an accelerated decline in their locomotor ability that increased as the ﬂies
aged. Similar defects in locomotor activity have been reported for Drosophila transgenic for mouse PrP, with or
without a 3F4 epitope, carrying the GSS-associated P102L mutation [67,68,70]. In our studies reported here,
the defect in locomotor activity was more evident in Drosophila that expressed mo3F4CJD or haCJDcompared
with those that expressed mo3F4FFI or haFFI. Furthermore, Drosophila transgenic for hamster PrP variants
Figure 8. Fly-to-ﬂy transmission of spontaneous neurotoxicity.
Drosophila transgenic for pan neuronal expression of mo3F4WT PrP (a) and (b) or haWT PrP (c) and (d) were exposed at the
larval stage to head homogenate from 30-day-old Drosophila transgenic for pan neuronal expression of control PrP [mo3F4WT
PrP transgenic Drosophila in (a) and (b), and haWT PrP transgenic Drosophila in (c) and (d)], green line; mo3F4CJD or haCJD PrP
transgenic Drosophila (where appropriate), red line; mo3F4FFI or haFFI PrP transgenic Drosophila (where appropriate), blue line.
Mouse 3F4 PrP transgenic inocula were from ﬂies maintained at 25°C (a) and (b); hamster PrP transgenic inocula were from
ﬂies maintained at 20°C (c) and (d). After hatching, adult Drosophila were assessed for their locomotor ability by a
negative-geotaxis climbing assay. The data shown are linear regression plots of the mean PI ± SD for three groups of ﬂies per
time point calculated as described in the Materials and Methods. Black line represents PI of uninoculated non-transgenic
control 51D ﬂies crossed with the elav-GAL4 pan neuronal driver ﬂy line. Statistical analysis was performed by using one-way
ANOVA and Tukey HSD for post hoc analysis.
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generally showed a more severe neurotoxic phenotype than ﬂies transgenic for mo3F4FFI or mo3F4CJD PrP.
The neurotoxicity we observed in mutant PrP transgenic Drosophila is similar to that seen in ovine PrP trans-
genic Drosophila exposed to sheep scrapie prions [48–51]. We reasoned that the phenotype seen in mutant PrP
transgenic Drosophila was associated with spontaneous prion formation since these ﬂies were not exposed to a
source of exogenous prion infectivity. Furthermore, prion-mediated toxicity in hosts that express PrP is consid-
ered to be due to conversion of the protein into an abnormal disease-associated conformer concomitant with
transmissible prion formation [2,3,5–8]. In this context, we investigated transmissibility of the spontaneous
neurotoxic phenotype in PrP transgenic Drosophila by secondary passage in recipient PrP transgenic
Drosophila (i.e. ﬂy-to-ﬂy transmission). Head homogenate from aged adult Drosophila transgenic for FFI or
fCJD mouse 3F4 or hamster PrP stimulated an accelerated decline in the locomotor ability in recipient
Drosophila transgenic for mo3F4WT PrP or haWT PrP, respectively, compared with the response seen with
control ﬂy head homogenate. We have previously shown that Drosophila transgenic for anchorless (ΔGPI)
ovine PrP develop a spontaneous neurotoxic phenotype that is transmissible to ﬂies that express wild-type
ovine PrP [48]. Non-sense mutations in the C-terminal GPI-signal sequence of human PrP, such as Y226X and
Q227X transitions, lead to the expression of an anchorless form of the prion protein that are associated with
GSS disease [71]. Collectively, therefore, our data presented here, together with our previous ﬁndings [48],
show that Drosophila transgenic for PrP harbouring fCJD- or FFI-associated mutations, or a GSS-related trun-
cated form of PrP, develop a spontaneous transferable neurotoxic phenotype. These observations are compatible
with spontaneous prion formation in these novel PrP transgenic hosts.
Mice have been used extensively as an experimental system in attempts to model human genetic prion
disease. Accordingly, a large number of PrP transgenic mouse lines have been produced, either by random
transgenesis on a PrP−/− background or direct knockin replacement of the endogenous mouse PrP gene, with
a speciﬁc prion protein transgene of interest, that harbours mutations associated with genetic forms of human
prion disease, or that carry alterations in the PrP polypeptide backbone. However, the majority of these PrP
transgenic mouse lines produced little, if any, bona ﬁde PK-resistant PrPSc [34] and while several of these
mouse lines developed neurodegenerative disease phenotypes, only a limited number have successfully been
used to demonstrate the generation of infectious prions de novo. In one example, knockin mice transgenic for
mo3F4FFI or mo3F4CJD PrP developed a spontaneous neurotoxic phenotype that was transmissible to mice that
express mo3F4WT PrP [27,28]. In our studies reported here, we have shown that inocula prepared from the
brains of knockin mice transgenic for mo3F4FFI or mo3F4CJD PrP can induce a neurotoxic phenotype in
Drosophila transgenic for mo3F4WT PrP. Furthermore, the time taken to detect spontaneously formed prions
by mouse-to-ﬂy transmission, which was completed in weeks, was considerably more rapid than
mouse-to-mouse transmission, which required more than 1 year [27,28]. Moreover, large numbers of
Drosophila could be used to enhance experimental design and improve statistical power, in contrast with mouse
experiments that have more signiﬁcant economic and ethical limitations. These observations highlight the
utility of PrP transgenic Drosophila to act in conjunction with more sentient mammalian hosts in the study of
human prion disease.
In our studies presented here, FFI or fCJD mouse 3F4 and hamster PrP variants were expressed pan neuron-
ally in the ﬂy, a situation analogous to prion protein expression in the natural host with a germ-line PRNP
mutation. As such, the possibility of cell autonomous mechanisms mediating the adverse effects of PrP misfold-
ing can be envisaged to occur. However, cell non-autonomous mechanisms, such as those associated with the
transcellular spread of misfolded PrP, may contribute to the pathogenesis of genetic forms of human prion
disease, as they must do in acquired cases, and potentially so in sporadic cases, of prion disease. Cell non-
autonomous pathogenic mechanisms are increasingly suggested to play a role in the pathogenesis of more
common human protein misfolding neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease
[72]. The process of transcellular spread of misfolded PrP can readily be studied in Drosophila through the
facile and versatile nature of transgenesis in the ﬂy, which allows simultaneous expression of mutant and wild-
type variants of the prion protein in distinct cell populations with the same host. This type of approach has
been used to suggest that phagocytic glia cells in Drosophila contribute to the mechanisms of both protein
aggregation-related neuroprotection and pathogenesis in protein misfolding neurodegenerative disease [73,74].
The application of this novel experimental approach to the study of genetic forms of human prion disease in
the ﬂy will complement our model of transmissible mammalian prion disease that we have established in PrP
transgenic Drosophila [48–51]. These new invertebrate models of mammalian prion disease will provide us
with the opportunity to exploit the power of genetics in the ﬂy to identify potential genetic modiﬁers of
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prion-induced neurotoxicity that may serve as candidate diagnostic markers or therapeutic targets of human
prion disease and prion-like diseases.
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